 |
CTSNet is sponsored in part by an educational
grant from |
 |
|
||
CRYOLIFE, INC. Home » Industry Forum » CRYOLIFE, INC.
1655 Roberts Boulevard, NW
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien® stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.
CryoLife, Inc., is a U.S. FDA-registered tissue processor and medical device manufacturer. CryoLife is in substantial compliance to the US FDA's Good Tissue Practices, which became effective May 25, 2005. In addition, CryoLife is licensed or registered as a tissue bank by the States of Georgia, New York, Florida, California, Illinois, Delaware, and Maryland and is an accredited member of the American Association of Tissue Banks. In substantial compliance with the laws of the European Union, CryoLife is certified to the international quality standards, ISO 13485, for the design, manufacture and distribution of tissues and medical devices. CryoLife is also in substantial compliance to the Canadian Human Tissue Regulations for the distribution of human tissue in Canada.
| ||||